In a small but welcome step toward medical care cost transparency, drug prices must appear in advertisements starting in July. That should benefit consumers and is the first of several possible steps the Trump administration may take on health care costs.
Alex Azar, the secretary of the U.S. Department of Health and Human Services, said the new regulation requires drug manufacturers to disclose the price of prescription medications costing more than $35 a month. The price will be listed toward the end of a television commercial or printed advertisement in legible text, along with the required listing of possible side effects of the drug.
The rule specifically is for drugs covered by Medicaid and Medicare programs, which includes most kinds of drugs.

Required will be the wholesale acquisition price, which, much like a car manufacturer’s suggested retail price on a vehicle, isn’t necessarily what a patient will pay, as insurance plans would negotiate discounts and then charge the plan’s out-of-pocket costs.
Drug companies ridiculed the regulation, saying consumers will be confused, that the price shown might lead patients to not get costly medications, and that the disclosure violates their First Amendment rights. Supporters of the rule, such as AARP, tout it as a positive step toward a much bigger problem of getting soaring prescription prices under control.
Prescription drug spending was more than $457 billion a year in the most recent government statistics, so price tags on medication are critical to consumers. For example, one frequently advertised drug, Xeljanz, a Pfizer arthritis product, costs about $4,840 a month, according to the website GoodRx. The drug market is extremely competitive — the industry spent $5.5 billion on medication advertising in 2017.
“Americans pay the highest for prescription drugs of anywhere in the world,” said Luke Russell, an AARP Ohio spokesman. Listing the price in advertisements is a good first step, he said, but getting negotiated prices, caps on out-of-pocket costs, and improving access to lower cost generic drugs also are key issues to be addressed. The Trump administration has voiced plans to tackle some of those issues this year.
This price listing move won’t bring down the cost of prescriptions but it will make consumers better informed. It might even prompt drug manufacturers to be embarrassed by the prices and lower them.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.